CD 101

Drug Profile

CD 101

Alternative Names: Biafungin™; CD 101 IV; CD 101 Topical; CD101; SP 3025

Latest Information Update: 01 Mar 2017

Price : $50

At a glance

  • Originator Seachaid Pharmaceuticals
  • Developer Cidara Therapeutics
  • Class Antifungals; Echinocandins; Small molecules
  • Mechanism of Action Glucan synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Candidiasis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Candidiasis; Vulvovaginal candidiasis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Candidiasis
  • Discontinued Vulvovaginal candidiasis

Most Recent Events

  • 21 Feb 2017 Discontinued - Phase-II for Vulvovaginal candidiasis in USA (Topical)
  • 21 Feb 2017 Top-line efficacy and adverse events data from a phase II trial in Vulvovaginal candidiasis (In women) released by Cidara Therapeutics
  • 04 Jan 2017 Cidara Therapeutics completes enrolment in the phase II RADIANT trial in Vulvovaginal candidiasis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top